June 13, 2013

Anna S. Lok, MD, on the future of hepatitis C treatment

Provided by Healio

June 13, 2013

ORLANDO, Fla. — Anna S. Lok, MD, discusses upcoming advancements in therapies for hepatitis C at Digestive Disease Week 2013.

Lok suggests that, with the emergence of new direct-acting antivirals within the next 5 years, the majority of patients with hepatitis C will be curable with a short course of once-daily, all-oral therapy with minimal side effects. Sustained virologic response rates of 80% to 90% will be possible with as few as 12 weeks of therapy, she estimated, with the lack of cross-resistance among new drugs of different classes allowing for potent, interferon-free treatment regimens. Lok anticipates FDA approval of two to three HCV medications by early 2014.

Source

0 comments :

Post a Comment